Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
Isabella Orienti,1 Giovanna Farruggia,1 Ferro Nguyen,2 Peng Guan,2 Natalia Calonghi,1 Venkatadri Kolla,2 Michael Chorny,2 Garrett M Brodeur2 1Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40127, Italy; 2Divisions of Oncology and Cardiology, Children’s Hospital of...
Guardado en:
Autores principales: | Orienti I, Farruggia G, Nguyen F, Guan P, Calonghi N, Kolla V, Chorny M, Brodeur GM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/df3a503fee734988935e74500c20ab27 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
por: Zhang L, et al.
Publicado: (2021) -
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel ME, et al.
Publicado: (2018) -
A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins GW, et al.
Publicado: (2020) -
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee B, et al.
Publicado: (2020) -
Systemic delivery of the anticancer agent arenobufagin using polymeric nanomicelles
por: Yuan X, et al.
Publicado: (2017)